Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 458

1.

Clinical promise of next-generation complement therapeutics.

Mastellos DC, Ricklin D, Lambris JD.

Nat Rev Drug Discov. 2019 Sep;18(9):707-729. doi: 10.1038/s41573-019-0031-6. Epub 2019 Jul 19. Review.

PMID:
31324874
2.

Cholesterol Crystals Induce Coagulation Activation through Complement-Dependent Expression of Monocytic Tissue Factor.

Gravastrand CS, Steinkjer B, Halvorsen B, Landsem A, Skjelland M, Jacobsen EA, Woodruff TM, Lambris JD, Mollnes TE, Brekke OL, Espevik T, Rokstad AMA.

J Immunol. 2019 Aug 15;203(4):853-863. doi: 10.4049/jimmunol.1900503. Epub 2019 Jul 3.

3.

Complement C3 inhibition by compstatin Cp40 prevents intra- and extravascular hemolysis of red blood cells.

Baas I, Delvasto-Nuñez L, Ligthart P, Brouwer C, Folman C, Reis ES, Ricklin D, Lambris JD, Wouters D, de Haas M, Jongerius I, Zeerleder SS.

Haematologica. 2019 Jun 6. pii: haematol.2019.216028. doi: 10.3324/haematol.2019.216028. [Epub ahead of print]

4.

The Challenges and Promise of Complement Therapeutics for Ocular Diseases.

Park DH, Connor KM, Lambris JD.

Front Immunol. 2019 May 15;10:1007. doi: 10.3389/fimmu.2019.01007. eCollection 2019. Review.

5.

Corrigendum: Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction.

Karasu E, Nilsson B, Köhl J, Lambris JD, Huber-Lang M.

Front Immunol. 2019 May 3;10:994. doi: 10.3389/fimmu.2019.00994. eCollection 2019.

6.

New insights into the immune functions of complement.

Reis ES, Mastellos DC, Hajishengallis G, Lambris JD.

Nat Rev Immunol. 2019 Aug;19(8):503-516. doi: 10.1038/s41577-019-0168-x. Review.

PMID:
31048789
7.

Interlaboratory Comparison of Hydrogen-Deuterium Exchange Mass Spectrometry Measurements of the Fab Fragment of NISTmAb.

Hudgens JW, Gallagher ES, Karageorgos I, Anderson KW, Filliben JJ, Huang RY, Chen G, Bou-Assaf GM, Espada A, Chalmers MJ, Harguindey E, Zhang HM, Walters BT, Zhang J, Venable J, Steckler C, Park I, Brock A, Lu X, Pandey R, Chandramohan A, Anand GS, Nirudodhi SN, Sperry JB, Rouse JC, Carroll JA, Rand KD, Leurs U, Weis DD, Al-Naqshabandi MA, Hageman TS, Deredge D, Wintrode PL, Papanastasiou M, Lambris JD, Li S, Urata S.

Anal Chem. 2019 Jun 4;91(11):7336-7345. doi: 10.1021/acs.analchem.9b01100. Epub 2019 May 14.

PMID:
31045344
8.

Complementing the Cancer-Immunity Cycle.

Pio R, Ajona D, Ortiz-Espinosa S, Mantovani A, Lambris JD.

Front Immunol. 2019 Apr 12;10:774. doi: 10.3389/fimmu.2019.00774. eCollection 2019. Review.

9.

Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction.

Karasu E, Nilsson B, Köhl J, Lambris JD, Huber-Lang M.

Front Immunol. 2019 Mar 21;10:543. doi: 10.3389/fimmu.2019.00543. eCollection 2019. Review. Erratum in: Front Immunol. 2019 May 03;10:994.

10.

Complement-Dependent Mechanisms and Interventions in Periodontal Disease.

Hajishengallis G, Kajikawa T, Hajishengallis E, Maekawa T, Reis ES, Mastellos DC, Yancopoulou D, Hasturk H, Lambris JD.

Front Immunol. 2019 Mar 12;10:406. doi: 10.3389/fimmu.2019.00406. eCollection 2019. Review.

11.

Native State of Complement Protein C3d Analysed via Hydrogen Exchange and Conformational Sampling.

Devaurs D, Papanastasiou M, Antunes DA, Abella JR, Moll M, Ricklin D, Lambris JD, Kavraki LE.

Int J Comput Biol Drug Des. 2018;11(1-2):90-113. doi: 10.1504/IJCBDD.2018.090834. Epub 2018 Mar 24.

12.

C3 glomerulopathy - understanding a rare complement-driven renal disease.

Smith RJH, Appel GB, Blom AM, Cook HT, D'Agati VD, Fakhouri F, Fremeaux-Bacchi V, Józsi M, Kavanagh D, Lambris JD, Noris M, Pickering MC, Remuzzi G, de Córdoba SR, Sethi S, Van der Vlag J, Zipfel PF, Nester CM.

Nat Rev Nephrol. 2019 Mar;15(3):129-143. doi: 10.1038/s41581-018-0107-2. Review.

PMID:
30692664
13.

Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule.

Lombardi E, Matte A, Risitano AM, Ricklin D, Lambris JD, De Zanet D, Jokiranta ST, Martinelli N, Scambi C, Salvagno G, Bisoffi Z, Colato C, Siciliano A, Bortolami O, Mazzuccato M, Zorzi F, De Marco L, De Franceschi L.

Haematologica. 2019 May;104(5):919-928. doi: 10.3324/haematol.2018.198622. Epub 2019 Jan 10.

14.

Taming hemodialysis-induced inflammation: Are complement C3 inhibitors a viable option?

Mastellos DC, Reis ES, Biglarnia AR, Waldman M, Quigg RJ, Huber-Lang M, Seelen MA, Daha MR, Lambris JD.

Clin Immunol. 2019 Jan;198:102-105. doi: 10.1016/j.clim.2018.11.010. Epub 2018 Nov 22.

PMID:
30472267
15.

Reduced Terminal Complement Complex Formation in Mice Manifests in Low Bone Mass and Impaired Fracture Healing.

Mödinger Y, Rapp AE, Vikman A, Ren Z, Fischer V, Bergdolt S, Haffner-Luntzer M, Song WC, Lambris JD, Huber-Lang M, Neidlinger-Wilke C, Brenner RE, Ignatius A.

Am J Pathol. 2019 Jan;189(1):147-161. doi: 10.1016/j.ajpath.2018.09.011. Epub 2018 Oct 17.

16.

Complement C5a-Mediated TAM-ing of Antitumor Immunity Drives Squamous Carcinogenesis.

Mastellos DC, Reis ES, Lambris JD.

Cancer Cell. 2018 Oct 8;34(4):531-533. doi: 10.1016/j.ccell.2018.09.005.

PMID:
30300576
17.

Short Leucine-Rich Proteoglycans Modulate Complement Activity and Increase Killing of the Respiratory Pathogen Moraxella catarrhalis.

Laabei M, Liu G, Ermert D, Lambris JD, Riesbeck K, Blom AM.

J Immunol. 2018 Nov 1;201(9):2721-2730. doi: 10.4049/jimmunol.1800734. Epub 2018 Sep 28.

PMID:
30266767
18.

Safety profile after prolonged C3 inhibition.

Reis ES, Berger N, Wang X, Koutsogiannaki S, Doot RK, Gumas JT, Foukas PG, Resuello RRG, Tuplano JV, Kukis D, Tarantal AF, Young AJ, Kajikawa T, Soulika AM, Mastellos DC, Yancopoulou D, Biglarnia AR, Huber-Lang M, Hajishengallis G, Nilsson B, Lambris JD.

Clin Immunol. 2018 Dec;197:96-106. doi: 10.1016/j.clim.2018.09.004. Epub 2018 Oct 10.

PMID:
30217791
19.

Gingival Exudatome Dynamics Implicate Inhibition of the Alternative Complement Pathway in the Protective Action of the C3 Inhibitor Cp40 in Nonhuman Primate Periodontitis.

Bostanci N, Bao K, Li X, Maekawa T, Grossmann J, Panse C, Briones RA, Resuello RRG, Tuplano JV, Garcia CAG, Reis ES, Lambris JD, Hajishengallis G.

J Proteome Res. 2018 Sep 7;17(9):3153-3175. doi: 10.1021/acs.jproteome.8b00263. Epub 2018 Aug 29.

20.

Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

Mastellos DC, Reis ES, Yancopoulou D, Risitano AM, Lambris JD.

Semin Hematol. 2018 Jul;55(3):167-175. doi: 10.1053/j.seminhematol.2018.02.002. Epub 2018 Feb 14. Review.

21.

Novel Immunoassay for Complement Activation by PF4/Heparin Complexes.

Khandelwal S, Johnson AM, Liu J, Keire D, Sommers C, Ravi J, Lee GM, Lambris JD, Reis ES, Arepally GM.

Thromb Haemost. 2018 Aug;118(8):1484-1487. doi: 10.1055/s-0038-1660858. Epub 2018 Jun 30. No abstract available.

22.

New Analogs of the Complement C3 Inhibitor Compstatin with Increased Solubility and Improved Pharmacokinetic Profile.

Berger N, Alayi TD, Resuello RRG, Tuplano JV, Reis ES, Lambris JD.

J Med Chem. 2018 Jul 26;61(14):6153-6162. doi: 10.1021/acs.jmedchem.8b00560. Epub 2018 Jul 3.

PMID:
29920096
23.

Functional Relevance of the Anaphylatoxin Receptor C3aR for Platelet Function and Arterial Thrombus Formation Marks an Intersection Point Between Innate Immunity and Thrombosis.

Sauter RJ, Sauter M, Reis ES, Emschermann FN, Nording H, Ebenhöch S, Kraft P, Münzer P, Mauler M, Rheinlaender J, Madlung J, Edlich F, Schäffer TE, Meuth SG, Dürschmied D, Geisler T, Borst O, Gawaz M, Kleinschnitz C, Lambris JD, Langer HF.

Circulation. 2018 Oct 16;138(16):1720-1735. doi: 10.1161/CIRCULATIONAHA.118.034600. Erratum in: Circulation. 2019 Jan 15;139(3):e8.

PMID:
29802205
24.

Innate immune responses to trauma.

Huber-Lang M, Lambris JD, Ward PA.

Nat Immunol. 2018 Apr;19(4):327-341. doi: 10.1038/s41590-018-0064-8. Epub 2018 Mar 5. Review.

25.

The Complement System Is Critical in Maintaining Retinal Integrity during Aging.

Mukai R, Okunuki Y, Husain D, Kim CB, Lambris JD, Connor KM.

Front Aging Neurosci. 2018 Feb 15;10:15. doi: 10.3389/fnagi.2018.00015. eCollection 2018.

26.

Protective Effects of the Complement Inhibitor Compstatin CP40 in Hemorrhagic Shock.

van Griensven M, Ricklin D, Denk S, Halbgebauer R, Braun CK, Schultze A, Hönes F, Koutsogiannaki S, Primikyri A, Reis E, Messerer D, Hafner S, Radermacher P, Biglarnia AR, Resuello RRG, Tuplano JV, Mayer B, Nilsson K, Nilsson B, Lambris JD, Huber-Lang M.

Shock. 2019 Jan;51(1):78-87. doi: 10.1097/SHK.0000000000001127.

PMID:
29461464
27.

Factor H C-Terminal Domains Are Critical for Regulation of Platelet/Granulocyte Aggregate Formation.

Blatt AZ, Saggu G, Cortes C, Herbert AP, Kavanagh D, Ricklin D, Lambris JD, Ferreira VP.

Front Immunol. 2017 Nov 23;8:1586. doi: 10.3389/fimmu.2017.01586. eCollection 2017.

28.

The renaissance of complement therapeutics.

Ricklin D, Mastellos DC, Reis ES, Lambris JD.

Nat Rev Nephrol. 2018 Jan;14(1):26-47. doi: 10.1038/nrneph.2017.156. Epub 2017 Dec 4. Review.

29.

Novel mechanisms and functions of complement.

Hajishengallis G, Reis ES, Mastellos DC, Ricklin D, Lambris JD.

Nat Immunol. 2017 Nov 16;18(12):1288-1298. doi: 10.1038/ni.3858. Review.

30.

Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression.

Kwak JW, Laskowski J, Li HY, McSharry MV, Sippel TR, Bullock BL, Johnson AM, Poczobutt JM, Neuwelt AJ, Malkoski SP, Weiser-Evans MC, Lambris JD, Clambey ET, Thurman JM, Nemenoff RA.

Cancer Res. 2018 Jan 1;78(1):143-156. doi: 10.1158/0008-5472.CAN-17-0240. Epub 2017 Nov 8.

31.

Factor H-IgG Chimeric Proteins as a Therapeutic Approach against the Gram-Positive Bacterial Pathogen Streptococcus pyogenes.

Blom AM, Magda M, Kohl L, Shaughnessy J, Lambris JD, Ram S, Ermert D.

J Immunol. 2017 Dec 1;199(11):3828-3839. doi: 10.4049/jimmunol.1700426. Epub 2017 Oct 30.

32.

Complement receptors C5aR1 and C5aR2 act differentially during the early immune response after bone fracture but are similarly involved in bone repair.

Kovtun A, Bergdolt S, Hägele Y, Matthes R, Lambris JD, Huber-Lang M, Ignatius A.

Sci Rep. 2017 Oct 25;7(1):14061. doi: 10.1038/s41598-017-14444-3.

33.

Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4.

Wang H, Ricklin D, Lambris JD.

Proc Natl Acad Sci U S A. 2017 Oct 10;114(41):10948-10953. doi: 10.1073/pnas.1707364114. Epub 2017 Sep 26.

34.

Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy.

Facciabene A, De Sanctis F, Pierini S, Reis ES, Balint K, Facciponte J, Rueter J, Kagabu M, Magotti P, Lanitis E, DeAngelis RA, Buckanovich RJ, Song WC, Lambris JD, Coukos G.

Oncoimmunology. 2017 Jun 8;6(9):e1326442. doi: 10.1080/2162402X.2017.1326442. eCollection 2017.

35.

Complement in cancer: untangling an intricate relationship.

Reis ES, Mastellos DC, Ricklin D, Mantovani A, Lambris JD.

Nat Rev Immunol. 2018 Jan;18(1):5-18. doi: 10.1038/nri.2017.97. Epub 2017 Sep 18. Review.

36.

Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates.

Kajikawa T, Briones RA, Resuello RRG, Tuplano JV, Reis ES, Hajishengallis E, Garcia CAG, Yancopoulou D, Lambris JD, Hajishengallis G.

Mol Ther Methods Clin Dev. 2017 Aug 18;6:207-215. doi: 10.1016/j.omtm.2017.08.001. eCollection 2017 Sep 15.

37.

Porphyromonas gingivalis disturbs host-commensal homeostasis by changing complement function.

Olsen I, Lambris JD, Hajishengallis G.

J Oral Microbiol. 2017 Jun 30;9(1):1340085. doi: 10.1080/20002297.2017.1340085. eCollection 2017. Review.

38.

Complement C5a-Induced Changes in Neutrophil Morphology During Inflammation.

Denk S, Taylor RP, Wiegner R, Cook EM, Lindorfer MA, Pfeiffer K, Paschke S, Eiseler T, Weiss M, Barth E, Lambris JD, Kalbitz M, Martin T, Barth H, Messerer DAC, Gebhard F, Huber-Lang MS.

Scand J Immunol. 2017 Sep;86(3):143-155. doi: 10.1111/sji.12580.

39.

Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses.

Xue X, Wu J, Ricklin D, Forneris F, Di Crescenzio P, Schmidt CQ, Granneman J, Sharp TH, Lambris JD, Gros P.

Nat Struct Mol Biol. 2017 Aug;24(8):643-651. doi: 10.1038/nsmb.3427. Epub 2017 Jul 3.

40.

Iron oxide nanoparticles induce cytokine secretion in a complement-dependent manner in a human whole blood model.

Wolf-Grosse S, Rokstad AM, Ali S, Lambris JD, Mollnes TE, Nilsen AM, Stenvik J.

Int J Nanomedicine. 2017 May 23;12:3927-3940. doi: 10.2147/IJN.S136453. eCollection 2017.

41.

Alginate microbeads are coagulation compatible, while alginate microcapsules activate coagulation secondary to complement or directly through FXII.

Gravastrand C, Hamad S, Fure H, Steinkjer B, Ryan L, Oberholzer J, Lambris JD, Lacík I, Mollnes TE, Espevik T, Brekke OL, Rokstad AM.

Acta Biomater. 2017 Aug;58:158-167. doi: 10.1016/j.actbio.2017.05.052. Epub 2017 May 30.

42.

Complement component C3aR constitutes a novel regulator for chick eye morphogenesis.

Grajales-Esquivel E, Luz-Madrigal A, Bierly J, Haynes T, Reis ES, Han Z, Gutierrez C, McKinney Z, Tzekou A, Lambris JD, Tsonis PA, Del Rio-Tsonis K.

Dev Biol. 2017 Aug 1;428(1):88-100. doi: 10.1016/j.ydbio.2017.05.019. Epub 2017 May 30.

43.

Complement C5a Functions as a Master Switch for the pH Balance in Neutrophils Exerting Fundamental Immunometabolic Effects.

Denk S, Neher MD, Messerer DAC, Wiegner R, Nilsson B, Rittirsch D, Nilsson-Ekdahl K, Weckbach S, Ignatius A, Kalbitz M, Gebhard F, Weiss ME, Vogt J, Radermacher P, Köhl J, Lambris JD, Huber-Lang MS.

J Immunol. 2017 Jun 15;198(12):4846-4854. doi: 10.4049/jimmunol.1700393. Epub 2017 May 10.

44.

Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery.

Mastellos DC, Reis ES, Ricklin D, Smith RJ, Lambris JD.

Trends Immunol. 2017 Jun;38(6):383-394. doi: 10.1016/j.it.2017.03.003. Epub 2017 Apr 14.

45.

Coarse-Grained Conformational Sampling of Protein Structure Improves the Fit to Experimental Hydrogen-Exchange Data.

Devaurs D, Antunes DA, Papanastasiou M, Moll M, Ricklin D, Lambris JD, Kavraki LE.

Front Mol Biosci. 2017 Mar 10;4:13. doi: 10.3389/fmolb.2017.00013. eCollection 2017.

46.

Structural Implications for the Formation and Function of the Complement Effector Protein iC3b.

Papanastasiou M, Koutsogiannaki S, Sarigiannis Y, Geisbrecht BV, Ricklin D, Lambris JD.

J Immunol. 2017 Apr 15;198(8):3326-3335. doi: 10.4049/jimmunol.1601864. Epub 2017 Mar 3.

47.

Pericytes and immune cells contribute to complement activation in tubulointerstitial fibrosis.

Xavier S, Sahu RK, Landes SG, Yu J, Taylor RP, Ayyadevara S, Megyesi J, Stallcup WB, Duffield JS, Reis ES, Lambris JD, Portilla D.

Am J Physiol Renal Physiol. 2017 Mar 1;312(3):F516-F532. doi: 10.1152/ajprenal.00604.2016. Epub 2017 Jan 4.

48.

Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.

Harder MJ, Kuhn N, Schrezenmeier H, Höchsmann B, von Zabern I, Weinstock C, Simmet T, Ricklin D, Lambris JD, Skerra A, Anliker M, Schmidt CQ.

Blood. 2017 Feb 23;129(8):970-980. doi: 10.1182/blood-2016-08-732800. Epub 2016 Dec 27.

49.

Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS.

Primikyri A, Papanastasiou M, Sarigiannis Y, Koutsogiannaki S, Reis ES, Tuplano JV, Resuello RR, Nilsson B, Ricklin D, Lambris JD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jan 15;1041-1042:19-26. doi: 10.1016/j.jchromb.2016.12.004. Epub 2016 Dec 6.

50.

Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies.

Evgin L, Ilkow CS, Bourgeois-Daigneault MC, de Souza CT, Stubbert L, Huh MS, Jennings VA, Marguerie M, Acuna SA, Keller BA, Lefebvre C, Falls T, Le Boeuf F, Auer RA, Lambris JD, McCart JA, Stojdl DF, Bell JC.

Mol Ther Oncolytics. 2016 Nov 16;3:16027. eCollection 2016.

Supplemental Content

Loading ...
Support Center